UCLA's Electric Field-Induced Release and Measurement (EFIRM) system could offer the early detection of cancers and other ...

The company's laboratory-developed test (LDT) for neurofilament light chain (NfL) also gained New York state approval as part of the permitting process.

Financial and other terms of the deal were not disclosed.

The program offers lower-cost, refurbished testing instruments as well as customer education, inventory management, and enhanced service agreements.

TBI is a potential new application area for the 8-year-old company, while it continues to commercialize its stroke triage ...

The all-virtual program is currently looking for a second cohort of novel diagnostics technologies, with a Sept. 30 deadline for new applications.

NEW YORK — The Scottish government has earmarked £800,000 ($1.1 million) to support the introduction of a Genedrive test to help prevent antibiotic-induced deafness in newborns within the country, ...

According to a company executive, the transactions will provide QuidelOrtho with greater financial flexibility while funding its continued growth.

WASHINGTON – In a presentation this week at the Next Generation Dx conference here, the National Cancer Institute's Wendy Rubinstein gave an update on the NCI's Vanguard study of multi-cancer early ...

NEW YORK – AdvaMed, along with 66 other stakeholder groups, sent a letter to US Centers for Medicare and Medicaid Services Administrator Mehmet Oz on Wednesday urging the agency to create a pathway ...

NEW YORK – Agilent Technologies said Wednesday that it has received US Food and Drug Administration approval for a companion diagnostic test to inform the treatment of patients with mismatch repair ...